Display options
Cite
Campbell BK, Fillingim RB, Lee S, et al. Effects of High-Dose Capsaicin on TMD Subjects: A Randomized Clinical Study. JDR Clin Trans Res. 2016;2(1):58-65doi: 10.1177/2380084416675837.
Campbell, B. K., Fillingim, R. B., Lee, S., Brao, R., Price, D. D., & Neubert, J. K. (2017). Effects of High-Dose Capsaicin on TMD Subjects: A Randomized Clinical Study. JDR clinical and translational research, 2(1), 58-65. https://doi.org/10.1177/2380084416675837
Campbell, B K, et al. "Effects of High-Dose Capsaicin on TMD Subjects: A Randomized Clinical Study." JDR clinical and translational research vol. 2,1 (2017): 58-65. doi: https://doi.org/10.1177/2380084416675837
Campbell BK, Fillingim RB, Lee S, Brao R, Price DD, Neubert JK. Effects of High-Dose Capsaicin on TMD Subjects: A Randomized Clinical Study. JDR Clin Trans Res. 2017 Jan;2(1):58-65. doi: 10.1177/2380084416675837. Epub 2016 Oct 26. PMID: 28879245; PMCID: PMC5576044.
Copy Download .nbib Format: NLM
Share it on

JDR Clin Trans Res. 2017 Jan;2(1):58-65. doi: 10.1177/2380084416675837. Epub 2016 Oct 26.

Effects of High-Dose Capsaicin on TMD Subjects: A Randomized Clinical Study.

JDR clinical and translational research

B K Campbell, R B Fillingim, S Lee, R Brao, D D Price, J K Neubert

Affiliations

  1. Magnolia Orthodontics, Hickory, NC, USA.
  2. Department of Community Dentistry and Behavioral Science, College of Dentistry, University of Florida, Gainesville, FL, USA.
  3. Department of Orthodontics, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Korea.
  4. Department of Orthodontics, College of Dentistry, University of Florida, Gainesville, FL, USA.
  5. Department of Oral Surgery and Diagnostic Sciences, College of Dentistry, University of Florida, Gainesville, FL, USA.

PMID: 28879245 PMCID: PMC5576044 DOI: 10.1177/2380084416675837

Abstract

Temporomandibular joint disorder (TMD) is a complex musculoskeletal disorder that presents with pain, limited jaw opening, and abnormal noises in the temporomandibular joint. Despite the significant impact that TMD has in terms of suffering and financial burden, relatively few new treatments have emerged; therefore, development of novel treatments to treat TMD pain remains a high priority. The rationale of this study was to use a double-blind, vehicle-controlled clinical trial to evaluate the effects of a high-concentration (8%) capsaicin cream on TMD. This is based on the hypothesis that targeting TRP vanilloid subfamily member 1 (TRPV1) for pain control may provide a novel method for pain relief in TMD patients. TRPV1 is primarily expressed on a population of nociceptive-specific neurons and provides a candidate target for the development of pain treatments. Capsaicin is the primary agonist for TRPV1 and has been used previously in relatively low doses (0.025% to 0.075%) as a therapeutic for a variety of pain disorders, including postherpetic neuralgia and osteoarthritis; however, analgesic efficacy remains equivocal. TMD and healthy control subjects were assigned to either an active capsaicin or vehicle control group. The treatments were applied for 2 h and then removed. Quantitative sensory testing (QST) was completed prior to drug application (baseline), 2 h after drug application, and 1 wk later. Perceived pain intensity was measured using a visual analog scale (VAS) following capsaicin or vehicle cream application. Significantly lower pain was reported in the week after application in the capsaicin-treated TMD subjects. For QST measures, there was a decreased thermal pain threshold 2 h after capsaicin application for both the control and TMD groups, but this resolved within a week. Capsaicin had no effect on pressure pain threshold or mechanical sensitivity in both TMD and healthy individuals. This study demonstrates that 8% topical capsaicin therapy is a relatively safe, simple, and effective treatment for patients with TMD.

Keywords: TRPV1; clinical study; neuropharmacology; neuroscience/neurobiology; orofacial pain; pain

Conflict of interest statement

The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.

References

  1. Trends Pharmacol Sci. 2002 Apr;23(4):183-91 - PubMed
  2. Pain. 1999 May;81(1-2):135-45 - PubMed
  3. J Clin Invest. 2004 May;113(9):1344-52 - PubMed
  4. Curr Opin Neurobiol. 2003 Aug;13(4):487-92 - PubMed
  5. Clin Ther. 1993 May-Jun;15(3):510-26 - PubMed
  6. J Med Chem. 2004 May 20;47(11):2717-23 - PubMed
  7. Brain Res Brain Res Rev. 2002 Oct;40(1-3):29-44 - PubMed
  8. J Am Dent Assoc. 1993 Oct;124(10):115-21 - PubMed
  9. J Pain. 2013 Dec;14(12 Suppl):T20-32.e1-3 - PubMed
  10. Annu Rev Neurosci. 2001;24:487-517 - PubMed
  11. J Craniomandib Disord. 1992 Fall;6(4):301-55 - PubMed
  12. J Orofac Pain. 2008 Spring;22(2):97-107 - PubMed
  13. Clin Ther. 1991 May-Jun;13(3):383-95 - PubMed
  14. J Neurobiol. 2004 Oct;61(1):3-12 - PubMed
  15. Eur J Pain. 2014 May;18(5):671-9 - PubMed
  16. Pain. 2004 Oct;111(3):360-7 - PubMed
  17. Cephalalgia. 2015 May;35(6):545-50 - PubMed
  18. J Orofac Pain. 2000 Winter;14(1):31-6 - PubMed
  19. Nat Rev Drug Discov. 2009 Jan;8(1):55-68 - PubMed
  20. J Rheumatol. 1992 Apr;19(4):604-7 - PubMed
  21. Crit Rev Oral Biol Med. 1997;8(3):291-305 - PubMed
  22. Curr Med Res Opin. 2013 Jun;29(6):673-83 - PubMed
  23. BMJ. 2004 Apr 24;328(7446):991 - PubMed
  24. Pain. 2003 Jul;104(1-2):219-28 - PubMed
  25. Science. 1979 Oct 26;206(4417):481-3 - PubMed
  26. J Neurol. 1991 Dec;238(8):452-6 - PubMed
  27. Pain. 2000 Nov;88(2):125-33 - PubMed
  28. Pain. 1983 Sep;17(1):45-56 - PubMed
  29. Pain Physician. 2014 Mar-Apr;17(2):E213-8 - PubMed

Publication Types

Grant support